Extruded extended release abuse deterrent pill
First Claim
Patent Images
1. An oral, extended release, abuse deterrent pill comprising:
- (i) 4 wt % to 35 wt % of an active substance susceptible to abuse, wherein the active substance is oxycodone, hydrocodone, hydromorphone, morphine, methadone, or pharmaceutical acceptable salts thereof;
(ii) 38 wt % to 42 wt % of polyethylene oxide as a matrix agent, wherein the matrix agent has an average molecular weight between 50K Daltons and 150K Daltons;
(iii) 15 wt % to 45 wt % of hydroxypropyl methylcellulose as a controlled release agent;
(iv) 0.2 wt % to 20 wt % polyethylene glycol as a plasticizer;
wherein the active substance susceptible to abuse has an extended release profile,wherein the pill exhibits less than a 10% increase in the release of the active substance in a simulated alcoholic gastric fluid environment,wherein the pill has at least 50 wt % of particles with a particle size greater than 0.5 mm following physical or mechanical manipulation of the pill, andwherein the pill is a formed, uniform extrudate having a uniform blend of active, matrix agent, controlled release agent and plasticizer, and is directly formed from an extrusion process.
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure relates to an oral, extended release, abuse deterrent pill containing at least one active pharmaceutical ingredient susceptible to abuse which is homogenously spread throughout a matrix used to deter abuse. The pill can be prepared using a hot melt extrusion process and a forming unit. The formed pill meets regulatory guidelines for extended release formulations and is abuse deterrent to parenteral administration due at least to particle size, viscosity, or purity limitations.
450 Citations
19 Claims
-
1. An oral, extended release, abuse deterrent pill comprising:
-
(i) 4 wt % to 35 wt % of an active substance susceptible to abuse, wherein the active substance is oxycodone, hydrocodone, hydromorphone, morphine, methadone, or pharmaceutical acceptable salts thereof; (ii) 38 wt % to 42 wt % of polyethylene oxide as a matrix agent, wherein the matrix agent has an average molecular weight between 50K Daltons and 150K Daltons; (iii) 15 wt % to 45 wt % of hydroxypropyl methylcellulose as a controlled release agent; (iv) 0.2 wt % to 20 wt % polyethylene glycol as a plasticizer; wherein the active substance susceptible to abuse has an extended release profile, wherein the pill exhibits less than a 10% increase in the release of the active substance in a simulated alcoholic gastric fluid environment, wherein the pill has at least 50 wt % of particles with a particle size greater than 0.5 mm following physical or mechanical manipulation of the pill, and wherein the pill is a formed, uniform extrudate having a uniform blend of active, matrix agent, controlled release agent and plasticizer, and is directly formed from an extrusion process. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
-
Specification